Naivek Develops New 'Dementia Innovative Drug' with 3x Increased Drug Delivery Efficiency

Naivek announced on the 7th that it has completed the development of a new formulation that increases the 'BBB penetration drug delivery efficiency' by more than three times compared to existing methods in the process of delivering gene drugs to the brain for the development of 'innovative new drugs' for the treatment of dementia and other brain diseases, and has also completed drug delivery efficiency testing.

Naivek's brain disease treatment substance is based on a drug delivery platform technology designed so that the drug administered into the blood in the form of nanoparticles is not decomposed and stably penetrates the blood-brain barrier (BBB), releasing the drug at the treatment site in the brain to produce therapeutic effects.

The reason most pharmaceutical companies fail to develop treatments for dementia and other brain diseases is that the therapeutic substances do not effectively penetrate the BBB. Naivek has already confirmed through external verification institutions that its self-developed blood-brain barrier (BBB) penetrating carrier, `NIPEP-TPP-BBB Shuttle (hereinafter BBB Shuttle)`, has about three times higher permeability compared to substances used by existing global pharmaceutical companies.

The most important factor when collaborating with overseas pharmaceutical companies, 'mechanism elucidation,' has also been completed. Without mechanism elucidation, joint research and license-out with global pharmaceutical companies are impossible, so Naivek has been actively discussing with global pharmaceutical companies based on the related carrier.

Naivek has already successfully completed the first joint research with the global pharmaceutical company Daiichi Sankyo and has entered the second joint research phase. Upon completion of the joint research, a 'joint development contract' with a technology transfer option or a 'license-out' contract is expected to be possible. Collaboration with global pharmaceutical companies is further expanding, including conducting tests for MTA with a U.S. pharmaceutical company.

The core of innovative new drug development for dementia and other brain diseases is BBB penetration technology. The BBB acts as the primary defense barrier that blocks external substances but also serves as an obstacle because therapeutic agents cannot penetrate it. Therefore, a drug delivery platform capable of penetrating the BBB is necessary to treat brain diseases such as Alzheimer's, Parkinson's, and brain tumors.

A Naivek official stated, "For brain disease treatment, not only BBB penetration but also a high level of drug delivery ratio is key. While most drug delivery platforms developed so far have a penetration rate of about 3-4% through the blood-brain barrier, Naivek has confirmed a high penetration rate of 9%."

This content was produced with the assistance of AI translation services.